<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Widmer, Jérôme</dc:creator>
  <dc:creator>Thauvin, Cédric</dc:creator>
  <dc:creator>Mottas, Inès</dc:creator>
  <dc:creator>Nguyen, Van Nga</dc:creator>
  <dc:creator>Delie, Florence</dc:creator>
  <dc:creator>Allémann, Eric</dc:creator>
  <dc:creator>Bourquin, Carole</dc:creator>
  <dc:date>2018-01-15</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Small-molecule agonists for the Toll-like receptors (TLR) 7 and 8 are effective for the  immunotherapy of skin cancer when used as topical agents. Their systemic use has  however been largely unsuccessful due to dose-limiting toxicity. We propose a  polymer-based nanodelivery system to target resiquimod, a TLR7 ligand, to the lymph  node in order to focus the immunostimulatory activity and to prevent a generalized  inflammatory response. We demonstrate successful encapsulation of resiquimod in  methoxypoly(ethylene glycol)-b-poly(DL-lactic acid) (mPEG-PLA) and mixed poly(DL- lactic-co-glycolic acid) (PLGA)/mPEG-PLA nanoparticles. We show that these  particles are taken up mainly by dendritic cells and macrophages, which are the prime  initiators of anticancer immune responses. Nanoparticles loaded with resiquimod  activate these cells, demonstrating the availability of the immune-stimulating cargo.  The unloaded particles are non-inflammatory and do not have cytotoxic activity on  immune cells. Following subcutaneous injection in mice, mPEG-PLA and  PLGA/mPEG-PLA nanoparticles are detected in dendritic cells and macrophages in  the draining lymph nodes, demonstrating the targeting potential of these particles.  Thus, polymer-based nanoparticles represent a promising delivery system that allows  lymph node targeting for small-molecule TLR7 agonists in the context of systemic  cancer immunotherapy.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/306530</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/306530/files/bou_pbn.pdf</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/306530/files/bou_pbn_sm.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ijpharm.2017.11.031</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>International Journal of Pharmaceutics. - 2018, vol. 535, no. 1, p. 444–451</dc:source>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Polymer-based nanoparticles loaded with a TLR7 ligand to target the lymph node for immunostimulation</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
